GeneOne Life Science resumes operations at US Plant 1, begins producing existing orders early next month
Predicted impact: Medium
US plant restart and early-month orders are meaningful for a small biotech; $106.5B won damages noted separately.
Comments
No comments yet. Start the conversation.
Comments are people's own views. Nothing here is financial advice.